Matthew Caufield
Stock Analyst at H.C. Wainwright
(4.40)
# 1,243
Out of 4,673 analysts
324
Total ratings
43.4%
Success rate
11.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALDX Aldeyra Therapeutics | Reiterated: Hold | $2 | $1.52 | +31.58% | 32 | Aug 17, 2026 | |
| KOD Kodiak Sciences | Reiterated: Buy | $58 | $38.33 | +51.32% | 16 | Aug 17, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $36 | $15.83 | +127.42% | 34 | Aug 14, 2026 | |
| ZBIO Zenas BioPharma | Reiterated: Buy | $44 | $32.29 | +36.27% | 16 | Aug 14, 2026 | |
| IMUX Immunic | Reiterated: Buy | $22 | $16.50 | +33.33% | 16 | Aug 13, 2026 | |
| LENZ LENZ Therapeutics | Reiterated: Buy | $38 | $4.68 | +711.97% | 18 | Aug 12, 2026 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $56 | $25.65 | +118.32% | 20 | Aug 12, 2026 | |
| UPB Upstream Bio | Reiterated: Buy | $36 | $6.97 | +416.50% | 2 | Aug 12, 2026 | |
| DMAC DiaMedica Therapeutics | Reiterated: Buy | $12 | $6.52 | +84.05% | 13 | Aug 11, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $8 | $4.05 | +97.53% | 36 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $23.99 | +83.41% | 10 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.89 | +362.72% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $72.70 | +21.05% | 11 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.9066 | +561.81% | 13 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $6 | $1.44 | +316.67% | 13 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $8.87 | +193.12% | 21 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.022 | n/a | 10 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.18 | n/a | 20 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $9.60 | n/a | 9 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $10.72 | n/a | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $79.81 | n/a | 5 | Oct 21, 2022 |
Aldeyra Therapeutics
Aug 17, 2026
Reiterated: Hold
Price Target: $2
Current: $1.52
Upside: +31.58%
Kodiak Sciences
Aug 17, 2026
Reiterated: Buy
Price Target: $58
Current: $38.33
Upside: +51.32%
4D Molecular Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $36
Current: $15.83
Upside: +127.42%
Zenas BioPharma
Aug 14, 2026
Reiterated: Buy
Price Target: $44
Current: $32.29
Upside: +36.27%
Immunic
Aug 13, 2026
Reiterated: Buy
Price Target: $22
Current: $16.50
Upside: +33.33%
LENZ Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $38
Current: $4.68
Upside: +711.97%
Mineralys Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $56
Current: $25.65
Upside: +118.32%
Upstream Bio
Aug 12, 2026
Reiterated: Buy
Price Target: $36
Current: $6.97
Upside: +416.50%
DiaMedica Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $12
Current: $6.52
Upside: +84.05%
Opus Genetics
Aug 10, 2026
Reiterated: Buy
Price Target: $8
Current: $4.05
Upside: +97.53%
Aug 10, 2026
Reiterated: Buy
Price Target: $44
Current: $23.99
Upside: +83.41%
Aug 7, 2026
Reiterated: Buy
Price Target: $18
Current: $3.89
Upside: +362.72%
Aug 7, 2026
Reiterated: Buy
Price Target: $88
Current: $72.70
Upside: +21.05%
Aug 6, 2026
Reiterated: Buy
Price Target: $6
Current: $0.9066
Upside: +561.81%
Aug 4, 2026
Maintained: Buy
Price Target: $8 → $6
Current: $1.44
Upside: +316.67%
Jul 31, 2026
Reiterated: Buy
Price Target: $26
Current: $8.87
Upside: +193.12%
Aug 22, 2025
Rated: Hold
Price Target: n/a
Current: $0.022
Upside: n/a
May 27, 2025
Rated: Hold
Price Target: n/a
Current: $3.18
Upside: n/a
May 19, 2025
Reiterated: Hold
Price Target: $9
Current: $9.60
Upside: n/a
Oct 29, 2024
Maintained: Buy
Price Target: $39
Current: $10.72
Upside: n/a
Oct 21, 2022
Rated: Hold
Price Target: n/a
Current: $79.81
Upside: n/a